山西医科大学学报2012，Vol.43Issue(4)：284-287,4.DOI:10.3969/J.ISSN.1007-6611.2012.04.013
门冬胰岛素30和赖脯胰岛素50对2型糖尿病疗效的对比观察
Comparative study on NovoRapid Mix30 and Humalog Mix50 in the treatment of type 2 diabetic patients
润琳 1王芳 1李恒 1张金惠1
作者信息
- 1. 西安市中心医院内分泌科,西安710030
- 折叠
摘要
Abstract
Objective To compare the clinical efficacy of NovoMix30 and Humalog MixSO in the treatment of type 2 diabetes raellitus (DM). Methods A randomized,controlled clinical trial of NovoMix30 and Hnmalog Mix50 was performed in the type 2 diabetic patients. Sixty patients were divided into two groups. The patients were treated with NovoMix30 in group A,and Humalog Mix50 in group B. The levels of fasting plasma glucose (FPG) .postprandial plasma glucose (PPG), hypoglycaemia, glucosylated hemoglobulin Ale (HbAl c) were compared before and after the treatment for 2 weeks, 3 months. Results After treatment for 2 weeks, the levels of HbAlc, FPG and PPG in two groups were all decreased significantly compared with the baselines. The decreased level of PPG 2 h in group B was significantly higher than in group A (P < 0.05). Incidence of hypogrycaemia in group A was higher than in group B (P < 0.05). The medical costs of decreasing glucose in group A was higher than in group B. Conclusion Humalog Mix50 is better than NovoMix30 for controling levels of PPG 2 h in patients with type 2 diabetes mellitus, and Humalog Mra50 is more economy.关键词
2型糖尿病/门冬胰岛素30/赖脯胰岛素50Key words
type 2 diabetes mellitus/ NovoMix30/ Humalog Mix50分类
医药卫生引用本文复制引用
润琳,王芳,李恒,张金惠..门冬胰岛素30和赖脯胰岛素50对2型糖尿病疗效的对比观察[J].山西医科大学学报,2012,43(4):284-287,4.
